Heather Wakelee
Academic Appointments
- Associate Professor - Med Center Line, Medicine - Oncology
- Member, Stanford Cancer Institute
Key Documents
Contact Information
-
Clinical Offices
Thoracic Oncology 875 Blake Wilbur Dr Rm 2233 MC 5826 Stanford, CA 94305 Tel Work (650) 723-9094 Fax (650) 724-3697
- Academic Offices
Personal Information Tel (650) 498-6000Not for medical emergencies or patient use
Professional Overview
Clinical Focus
- Cancer> Thoracic Oncology
- Lung Cancer - Medical Oncology
- Investigational Therapeutics
- Medical Oncology
- thymoma
- Mesothelioma
Honors and Awards
- Teaching Award, Stanford University Division of Oncology (2007, 2008, 2009, 2011)
- Alpha Omega Alpha, Johns Hopkins University (06/1996)
- Merit Award, American Society of Clinical Oncology (05/2003)
Professional Education
| Board Certification: | Medical Oncology, American Board of Internal Medicine (2003) |
| Internship: | Stanford University Medical Center CA (1997) |
| Medical Education: | Johns Hopkins University School of Medicine MD (1996) |
| M. D.: | Johns Hopkins University, Medicine (1996) |
| A.B.: | Princeton University, Molecular Biology (1992) |
Industry Relationships
Stanford is committed to ethical and transparent interactions with our industrial and other commercial partners. It is our policy to disclose payments (exclusive of travel support) from, and/or equity in, companies or other commercial entities to Stanford faculty of $5,000 or more in total value, as well as any equity in a privately held company, when the faculty member also has institutional responsibilities related to his or her interactions with the company. View Full Information
Scientific Focus
Current Research Interests
Dr. Wakelee is a clinical investigator with a focus in lung cancer and other thoracic malignancies. Along with her other colleagues in thoracic medical oncology at Stanford she is focused on clinical trials with agents that are specifically targeted to known mutations in lung cancer. These trials focus on EGFR targeted agents, and drugs which overcome resistance to traditional EGFR targeted drugs. She is also focusing on Met targeted drugs such as onartuzumab, tivantinib and cabozantinib. Earlier work on anti-angiogenesis agents continues as well.
Dr. Wakelee is an active member of the Eastern Cooperative Oncology Group and is the prinicipal investigator of a large adjuvant trial for patients with completely resected lung cancer who are randomized to chemotherapy or chemotherapy plus bevacizumab.
Thymic malignancies are an understudied rare disease and Dr. Wakelee has developed 2 clinical trials in this patient population. She serves as the chair of the research working group of the International Thymic Malignancies Interest Group (ITMIG) and is working to further expand the research portfolio in this patient population.
Dr. Wakelee is also involved in several collaborative efforts with her colleagues in thoracic surgery and radiation oncology (a multi-disciplinary trial for stage III non-small cell lung cancer patients and cyberknife protocols for early stage patients not eligible for surgery), as well as in pulmonary medicine (analysis of blood samples for circulating lung tumor cells and other basic science projects). She has active collaborations with population scientists at CPIC looking at lung cancer related questions. She is also very focused on exploring lung cancer questions in the Women's Health Initiative through collaborations with Marcia Stefanick.
Clinical Trials
- Recruiting Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
- Recruiting BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
- Recruiting Study to Evaluate Safety, Pharmacokinetics, and Preliminary Efficacy of CO-1686 in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) Non-Small Cell Lung Cancer (NSCLC)
- Recruiting Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Recruiting Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR
Publications
- A double-blind randomized discontinuation phase-II study of sorafenib (BAY 43-9006) in previously treated non-small-cell lung cancer patients: eastern cooperative oncology group study E2501. J Thorac Oncol. 2012; (10): 1574-82
- Lung cancer incidence in never smokers. J Clin Oncol. 2007; (5): 472-8
- A case series of NSCLC patients with different molecular characteristics and choroidal metastases: improvement in vision with treatment including pemetrexed and bevacizumab. J Thorac Oncol. 2013; (2): e17-8
- A patient with anaplastic lymphoma kinase-positive non-small cell lung cancer with development of leptomeningeal carcinomatosis while on targeted treatment with crizotinib. J Natl Compr Canc Netw. 2013; (4): 389-94
- Aflibercept in lung cancer. Expert Opin Biol Ther. 2013; (1): 115-20
- Phase I and pharmacokinetic study of bexarotene in combination with gefitinib in the third-line treatment of non-small-cell lung cancer: brief report. Anticancer Drugs. 2013
Help